Physician profile
Terry D Roode
NPI 1093749913
$979.27
in general payments reported to CMS, 2019-2025
12 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.35 · 2020: $52.08 · 2021: $27.71 · 2022: $182 · 2023: $378 · 2024: $145 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $642.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $246.87 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $151.90 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $148.16 | 2020-2024 | Mounjaro |
| Abbott Laboratories | $105.67 | 2023-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $98.01 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $49.39 | 2023-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $49.34 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $46.95 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $40.09 | 2022-2023 | Farxiga |
| Biohaven Pharmaceutical Holding Company LTD. | $16.50 | 2022 | |
| Allergan, INC. | $13.38 | 2020 | |
| Merck Sharp & Dohme LLC | $13.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Roode listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.